Abstract: Derivatives of oxazolidin-2-one of general formula (I) ##STR1## in which: n is equal to 0 or 1,R.sub.1 represents a cyano group, an alkyl group or a fluoroalkyl group,R.sub.2 represents a hydrogen atom or a hydroxyl group, andR.sub.3 represents a hydrogen atom or a methyl group.Application in therapeutics.

Abstract: Compounds of general formula (I) ##STR1## in which R.sub.1 represents a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl, (C.sub.3 -C.sub.6)cycloalkylmethyl or phenyl-(C.sub.1 -C.sub.3)alkyl group optionally substituted on the phenyl ring with one or more atoms or groups chosen from halogens and methyl, trifluoromethyl, methoxy and cyano groups, R.sub.2 represents a hydroxyl or alkoxy group or a group of general formula NR.sub.3 R.sub.4 in which R.sub.3 and R.sub.4 each represent a hydrogen atom, an alkyl group, a cycloalkyl group, a cycloalkylmethyl group, a phenyl group, a phenylmethyl group or a pyridyl group, or alternatively R.sub.3 and R.sub.4 form, together with the nitrogen atom, a pyrrolidine or piptzidine ring, and n represents the number 1, 2 or 3.Application in therapy.

Abstract: Use of a compound represented by the following general formula (I) ##STR1## where X is a group --CH-- or a nitrogen atom; R.sub.1 is a hydrogen atom, a benzyl group, a substituted benzyl group; a non-substituted heterocyclic methyl group wherein the heterocyclic part is a pyridyl, thienyl or furyl; or a substituted heterocyclic methyl group;R.sub.2 is a hydrogen atom or (C.sub.1-4) alkyl group;R.sub.3 is a hydrogen atom or hydroxy group;R.sub.4 is a hydrogen atom or (C.sub.1-4) alkyl group, its tautomer whenR.sub.3 is an hydroxy group, their pharmaceutically permissible acid addition salts, or any of their hydrates for preventing and/or treating rhinitis.

Abstract: Azacyloalkane derivatives of general formula ##STR1## in which: R.sub.1 and R.sub.2 represent a hydrogen atom, an alkyl group or a phenyl group, or R.sub.1 and R.sub.2 together form an oxo group, R.sub.3 represents a hydrogen atom or an alkyl group, or alternatively R.sub.3 forms a methylene group, R.sub.4 represents an aromatic group or, when R.sub.3 forms a methylene group, R.sub.4 represents a phenylene group in which one carbon atom is linked to Y and another carbon atom, adjacent to the preceding one, is linked to the said methylene group, R.sub.5 is either a group OR.sub.7, where R.sub.7 is a hydrogen atom or a benzyl group, or an N.sup.4 -methylpiperazinyl group, or alternatively a group NHR.sub.8 where R.sub.8 is a hydroxyl, pyridylmethyl or phenylmethyl group, A is an optionally substituted aromatic ring, n is equal to 1 or 2, X is CH, O or N, and Y is CH.sub.2, O or S, the process for preparing them and their applications in therapy.

Abstract: The present invention relates to isoindole derivatives, and more particularly to 5-(hydroxymethyl)oxazolidine-2-one derivatives which are substituted at the 3 position by an indazole, benzisoxazole or benzisothiazole ring system, to a process for their preparation and to their application in therapy.

Abstract: The present invention relates to a medical or surgical probe.According to the invention:the elongate body (2) of said probe includes a central longitudinal channel (4) delimiting, within said body, longitudinal portions (5, 6) connected to one another by surface material lines (8) which are easily tearable;each of said longitudinal portions of the body includes an internal longitudinal conduit (9, 10);each of the branches (11, 12) of the probe is formed by one such longitudinal portion of said body, separated from the other longitudinal portion; andthe cross section of said longitudinal channel (4) is capable of receiving a tubular element.

Abstract: The present invention provides a compound of formula (I) ##STR1## in which R.sub.1 represents a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group, R.sub.2 represents a hydrogen atom or a straight or branched (C.sub.1 -C.sub.4)alkyl group, R.sub.3 represents a straight or branched (C.sub.1 -C.sub.7)alkyl group, a group --(CH.sub.2).sub.n OCH.sub.3 (where n is 1, 2 or 3) or a group --CH.sub.2 O(C.sub.2 H.sub.4 O).sub.m CH.sub.3 (where m is 1, 2 or 3), R.sub.4 represents a hydrogen atom or a halogen atom, R.sub.5 represents a straight or branched (C.sub.1 -C.sub.4)alkyl group and A represents phenyl or heterocyclic group optionally substituted with one or more substituents independently chosen from halogen atoms and straight or branched (C.sub.1 -C.sub.4)alkyl, straight or branched (C.sub.1 -C.sub.4)alkoxy and trifluoromethyl groups, or a cyclo(C.sub.5 -C.sub.

Abstract: The present invention provides a compound of formula (1) ##STR1## in which: R.sub.4 represents a hydrogen atom, a halogen atom or a nitro group;R.sub.6 represents a hydrogen atom or a straight or branched (C.sub.1 -C.sub.6)alkyl group;R.sub.7 represents a chlorine atom or a hydroxyl group; andZ represents: a phenyl group optionally substituted with one or more halogen atoms, straight or branched (C.sub.1 -C.sub.4)alkyl groups, straight or branched (C.sub.1 -C.sub.4)alkoxy groups, or trifluoromethyl, formyl, --CH.sub.2 OR, --CH.sub.2 OCOR, --CH.sub.2 CONRR', --CH.sub.2 ONCOR, --COOR, nitro, --NHR, --NRR' or --NHCOR groups, wherein R and R' are each, independently, a hydrogen atom or a (C.sub.1 -C.sub.7)alkyl group; a heterocyclic group optionally substituted as defined above for phenyl; or a cyclo(C.sub.5 -C.sub.8)alkyl group; additionally, when R.sub.

Abstract: A process for the preparation of ethyl 4,4,4-trifluoro-3(R)-hydroxybutanoate, wherein the ester functional group of the (S) enantiomer of ethyl (.+-.)-4,4,4-trifluoro-3-hydroxybutanoate which comprises (R) and (S) is selectively hydrolysed in aqueous medium, by means of a lipase, and the non-hydrolysed (R) enantiomer is then extracted and used in the preparation of 4,4,4-trifluoro-1,3(R)-butanediol.

Abstract: The present invention provides a compound of formula (1) ##STR1## in which: R.sub.4 represents a hydrogen atom, a halogen atom or a nitro group;R.sub.6 represents a hydrogen atom or a straight or branched (C.sub.1 -C.sub.6) alkyl group;R.sub.7 represents a chlorine atom or a hydroxyl group; andZ represents: a phenyl group optionally substituted with one or more halogen atoms, straight or branched (C.sub.1 -C.sub.4)alkyl groups, straight or branched (C.sub.1 -C.sub.4)alkoxy groups, or trifluoromethyl, formyl, --CH.sub.2 OR, --CH.sub.2 OCOR, --CH.sub.2 CONRR', --CH.sub.2 ONCOR, --COOR, nitro, --NHR, --NRR' or --NHCOR groups, wherein R and R' are each, independently, a hydrogen atom or a (C.sub.1 -C.sub.7) alkyl group; a heterocyclic group optionally substituted as defined above for phenyl; or a cyclo(C.sub.5 -C.sub.8)alkyl group; additionally, when R.sub.

Abstract: Polyamine antagonists are found to be effective in preventing or reducing visual field loss associated with glaucoma. Especially preferred are certain 1-phenyl-2-piperidinoalkanol derivatives, such as eliprodil and ifenprodil.

Abstract: The method of use of the .alpha.-1 blockers, alfuzosine and terazosine, in the treatment of premature ejaculation is disclosed.

Abstract: Concentrated aqueous solutions of argatroban containing argatroban, a micelle-forming agent and a lipoid substance.

Abstract: Process for the preparation of one or both enantiomers of 1-(4-chlorophenyl)-2-chloroethanol, which comprises an enantioselective enzymatic hydrolysis of (.+-.)-.alpha.-(4-chlorophenyl)chloroethyl acetate by means of an enzyme which is horse liver acetone powder, lipase PS from Pseudomonas fluorescens, lipase AK from Pseudomonas or the lipase from Candida antarctica, to give a mixture of unhydrolysed R-(-)-.alpha.-(4-chlorophenyl)chloroethyl acetate and S-(+)-1-(4-chlorophenyl)-2-chloroethanol, and optional separation of R-(-)-.alpha.-(4-chlorophenyl)chloroethyl acetate and optional hydrolysis of it to give R-(-)-1-(4-chlorophenyl)-2-chloroethanol and use of the enantiomers of 1-(4-chlorophenyl)-2-chlorethanol for the preparation of the enantiomers of eliprodil and of their salts.

Abstract: Method of treating venous insufficiency and venous ulcers by administering to a patient in need thereof an effective amount of sulphasalazine or 5-aminosalicylic acid.

Abstract: A compound of formula (I) ##STR1## in which X represents a hydrogen atom, a halogen atom, a trifluoromethyl group, a C.sub.1 -C.sub.3 alkyl group or a C.sub.1 -C.sub.3 alkoxy group in which case two such alkoxy groups X can be present,Y represents a hydrogen atom, a halogen atom, a C.sub.1 -C.sub.3 alkyl group or a C.sub.1 -C.sub.3 alkoxy group,R.sub.1 represents C.sub.1 -C.sub.4 alkyl group, andR represents a hydroxyl group, a methoxy group, an ethoxy group or a group of formula NR.sub.2 R.sub.3 in which R.sub.2 and R.sub.3 each independently represents a hydrogen atom or a C.sub.1 -C.sub.4 alkyl group, or a pharmaceutically acceptable addition salt thereof, processes for their preparation and their therapeutic application.

Abstract: Compounds of the formula: ##STR1## in which R.sub.1 represents a hydrogen or halogen atom or a methyl or C.sub.1 -C.sub.4 alkoxy group, R'.sub.1 represents a hydrogen or halogen atom, R".sub.1 represents a hydrogen atom or a methoxy group, R.sub.3 represents a C.sub.1 -C.sub.3 alkyl group, R.sub.4 represents a 2,3-dihydro-1H-inden-2-yl, 2,3-dihydro-1H-inden-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group, or R.sub.3 and R.sub.4 together form, with the adjacent nitrogen atom, a 1,2,3,4-tetrahydroisoquinol-2-yl, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl, 5,8-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-3-yl, 4,5,6,7-tetrahydrothieno[2,3-c]pyrid-6-yl, 2,3-dihydro-1H-isoindol-2-yl or 2,3,4,5-tetra-hydro-1H-3-benzazepin-3-yl, group are useful in the treatment of cerebral disorders.

Abstract: An optically active isomer or a racemate of a compound of general formula (I) ##STR1## in which either R.sub.1 represents a methoxy or cyclopropylmethoxy group andR.sub.2 represents a hydrogen, chlorine or bromine atom, orR.sub.1 and R.sub.2 together form, and in this order, a group of formula --O--CH.sub.2 --O--, --O--(CH.sub.2).sub.2 --, --O--(CH.sub.2).sub.2 --O-- or --O--(CH.sub.2).sub.3 --O--,R.sub.3 represents a hydrogen atom or an amino group, andR.sub.4 represents a hydrogen, chlorine or bromine atom,in the form of a free base or of a pharmaceutically acceptable acid addition salt.

Abstract: Eliprodil, or an enantiomer thereof, is indicated for combined administration with anticancer agents in order to prevent peripheral neuropathies induced by administration of the anticancer agents.

Abstract: 3,3a,4,5-Tetrahydro-1H-oxazolo[3,4-a]quinolin-1-one derivatives of formula (I) ##STR1## in which: n is 0 or 1,R.sub.1 represents a hydrogen atom or an ethenyl, methyl, ethyl, phenyl, hydroxymethyl or methoxymethyl group, and(i) R.sub.2 is a methyl, trifluoromethyl or cyano group, R.sub.3 is a hydrogen atom or a hydroxyl or benzyloxy group and R.sub.4 and R.sub.5 are hydrogen atoms,or (ii) R.sub.2 and R.sub.4 together form a --(CH.sub.2).sub.4 -- group, R.sub.3 is a hydroxyl group and R.sub.5 is a hydrogen atom,or (iii) R.sub.2 and R.sub.5 together form an --O--(CH.sub.2).sub.3 -- group, and R.sub.3 and R.sub.4 are hydrogen atoms,or (iv) R.sub.2 and R.sub.5 together form a --(CH.sub.2).sub.4 group, R.sub.3 is a hydroxyl group and R.sub.4 is a hydrogen atom,are useful as selective inhibitors of MAO-A or as mixed inhibitors of MAO-A and MAO-B.